Biodexa Pharmaceuticals (BDRX) Payables (2013 - 2025)

Biodexa Pharmaceuticals (BDRX) has 13 years of Payables data on file, last reported at $7.3 million in Q4 2025.

• For the quarter ending Q4 2025, Payables rose 46.78% year-over-year to $7.3 million; the trailing twelve-month figure through Dec 2025 stood at $7.3 million (up 46.78% YoY), and the FY2025 full-year result was $7.3 million, up 45.49% from the prior year.
• Payables climbed to $7.3 million in Q4 2025, from $1.9 million in the prior quarter.
• In the past five years, Payables ranged from a high of $7.3 million in Q4 2025 to a low of $1.8 million in Q4 2022.
• A 5-year average of $3.8 million and a median of $3.1 million in 2024 frame the typical range for Payables.
• Across the five-year window, Payables slumped 64.68% in 2022 and jumped 272.98% in 2023, its largest moves.
• Tracing BDRX's Payables over 5 years: stood at $2.2 million in 2021, then slipped by 18.97% to $1.8 million in 2022, then jumped by 272.98% to $6.7 million in 2023, then fell by 25.56% to $5.0 million in 2024, then soared by 46.78% to $7.3 million in 2025.
• Business Quant data shows BDRX's Payables at $7.3 million in Q4 2025, $1.9 million in Q2 2025, and $5.0 million in Q4 2024.